BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33352993)

  • 21. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
    Zagiel B; Melnyk P; Cotelle P
    Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
    Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
    J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovering inhibitors of TEAD palmitate binding pocket through virtual screening and molecular dynamics simulation.
    Li Y; Li Y; Ning C; Yue J; Zhang C; He X; Wang Y; Liu Z
    Comput Biol Chem; 2022 Jun; 98():107648. PubMed ID: 35288361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression.
    Ning B; Tilston-Lunel AM; Simonetti J; Hicks-Berthet J; Matschulat A; Pfefferkorn R; Spira A; Edwards M; Mazzilli S; Lenburg ME; Beane JE; Varelas X
    J Exp Clin Cancer Res; 2023 May; 42(1):116. PubMed ID: 37150829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical and Structural Characterization of a Peptidic Inhibitor of the YAP:TEAD Interaction That Binds to the α-Helix Pocket on TEAD.
    Mesrouze Y; Gubler H; Villard F; Boesch R; Ottl J; Kallen J; Reid PC; Scheufler C; Marzinzik AL; Chène P
    ACS Chem Biol; 2023 Mar; 18(3):643-651. PubMed ID: 36825662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of FAM181A and FAM181B as new interactors with the TEAD transcription factors.
    Bokhovchuk F; Mesrouze Y; Delaunay C; Martin T; Villard F; Meyerhofer M; Fontana P; Zimmermann C; Erdmann D; Furet P; Scheufler C; Schmelzle T; Chène P
    Protein Sci; 2020 Feb; 29(2):509-520. PubMed ID: 31697419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence.
    Furet P; Salem B; Mesrouze Y; Schmelzle T; Lewis I; Kallen J; Chène P
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2316-2319. PubMed ID: 31235263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. YAP/TAZ-TEAD is a novel transcriptional regulator of genes encoding steroidogenic enzymes in rat granulosa cells and KGN cells.
    Mizutani T; Orisaka M; Kawabe S; Morichika R; Uesaka M; Yoshida Y
    Mol Cell Endocrinol; 2023 Jan; 559():111808. PubMed ID: 36309205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
    Chapeau EA; Sansregret L; Galli GG; Chène P; Wartmann M; Mourikis TP; Jaaks P; Baltschukat S; Barbosa IAM; Bauer D; Brachmann SM; Delaunay C; Estadieu C; Faris JE; Furet P; Harlfinger S; Hueber A; Jiménez Núñez E; Kodack DP; Mandon E; Martin T; Mesrouze Y; Romanet V; Scheufler C; Sellner H; Stamm C; Sterker D; Tordella L; Hofmann F; Soldermann N; Schmelzle T
    Nat Cancer; 2024 Apr; ():. PubMed ID: 38565920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation.
    Chan SW; Lim CJ; Loo LS; Chong YF; Huang C; Hong W
    J Biol Chem; 2009 May; 284(21):14347-58. PubMed ID: 19324876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
    Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
    Elife; 2022 Nov; 11():. PubMed ID: 36398861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling.
    Holden JK; Crawford JJ; Noland CL; Schmidt S; Zbieg JR; Lacap JA; Zang R; Miller GM; Zhang Y; Beroza P; Reja R; Lee W; Tom JYK; Fong R; Steffek M; Clausen S; Hagenbeek TJ; Hu T; Zhou Z; Shen HC; Cunningham CN
    Cell Rep; 2020 Jun; 31(12):107809. PubMed ID: 32579935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
    Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
    FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a Gene Signature That Predicts Dependence upon YAP/TAZ-TEAD.
    Kanai R; Norton E; Stern P; Hynes RO; Lamar JM
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
    Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP
    J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway.
    Chan P; Han X; Zheng B; DeRan M; Yu J; Jarugumilli GK; Deng H; Pan D; Luo X; Wu X
    Nat Chem Biol; 2016 Apr; 12(4):282-9. PubMed ID: 26900866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD⋅Yap Protein-Protein Interaction.
    Bum-Erdene K; Zhou D; Gonzalez-Gutierrez G; Ghozayel MK; Si Y; Xu D; Shannon HE; Bailey BJ; Corson TW; Pollok KE; Wells CD; Meroueh SO
    Cell Chem Biol; 2019 Mar; 26(3):378-389.e13. PubMed ID: 30581134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling.
    Noland CL; Gierke S; Schnier PD; Murray J; Sandoval WN; Sagolla M; Dey A; Hannoush RN; Fairbrother WJ; Cunningham CN
    Structure; 2016 Jan; 24(1):179-186. PubMed ID: 26724994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Transcriptional Enhanced Associate Domains (TEADs).
    Gibault F; Sturbaut M; Bailly F; Melnyk P; Cotelle P
    J Med Chem; 2018 Jun; 61(12):5057-5072. PubMed ID: 29251924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.